CBIO

Crescent Biopharma Inc

13.00

Oct 21 • 5:35 AM ET -0.07 (-0.54%)

Healthcare Biotechnology USA Small NASD

Peers: SMMT BCAX BNTX MGNX ZYME STRO CTMX PYXS WHWK XLO

| Held by: VTI IWM VXF XBI IWO VTWO IWC VHT VTWG VFMO

Index	RUT
Market Cap	482.87M
Enterprise Value	316.72M
Income	-165.12M
Sales	11.88M
Book/sh	5.74
Cash/sh	4.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	44
IPO	Jan 10, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	40.65
P/B	2.27
P/C	2.81
P/FCF	-
EV/EBITDA	-
EV/Sales	26.66
Quick Ratio	9.66
Current Ratio	9.66
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-7.65
EPS next Y	-2.91
EPS next Q	-0.67
EPS this Y	78.41%
EPS next Y	-5.24%
EPS next 5Y	37.95%
EPS past 3/5Y	45.01% 33.26%
Sales past 3/5Y	424.86% 1.31%
EPS Y/Y TTM	78.59%
Sales Y/Y TTM	-100.00%
EPS Q/Q	85.60%
Sales Q/Q	-
Earnings	Jul 30 BMO
EPS/Sales Surpr.	-0.58% -100.00%

Insider Own	16.78%
Insider Trans	14.07%
Inst Own	70.70%
Inst Trans	13.01%
ROA	-97.08%
ROE	-109.17%
ROIC	-100.55%
Gross Margin	98.22%
Oper. Margin	-1417.74%
Profit Margin	-1389.58%
SMA20	-4.91%
SMA50	-19.34%
SMA200	-17.79%
Trades

Shs Outstand	37.14M
Shs Float	30.91M
Short Float	15.46%
Short Ratio	13.23
Short Interest	4.78M
52W High	27.41 -52.57%
52W Low	8.72 49.08%
Volatility	8.61% 8.49%
ATR (14)	1.11
RSI (14)	39.96
Beta	1.38
Rel Volume	0.00
Avg Volume	361.22K
Volume	33

Perf Week	3.34%
Perf Month	-20.92%
Perf Quarter	-23.66%
Perf Half Y	-51.82%
Perf YTD	9.61%
Perf Year	2.77%
Perf 3Y	-89.68%
Perf 5Y	-93.23%
Perf 10Y	-97.98%
Recom	1.00
Target Price	31.50
Prev Close	13.07
Price	13.00
Change %	-0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-26	Upgrade	H.C. Wainwright	Neutral → Buy	$36
Jun-01-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-28-26	Initiated	Piper Sandler	Overweight	$35
Jan-21-26	Initiated	Guggenheim	Buy	$35
Aug-25-25	Initiated	Jefferies	Buy	$26
Aug-11-25	Initiated	H.C. Wainwright	Buy	$25
Jul-14-25	Initiated	Wedbush	Outperform	$27
Jun-25-25	Initiated	Stifel	Buy	$28
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Oct-15-26 04:15PM	Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 (GlobeNewswire) -5.13%
Oct-06-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Oct-05-26 07:30AM	Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors (GlobeNewswire)
Sep-25-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Sep-09-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
07:30AM	Loading…
Sep-03-26 07:30AM	Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire) +10.03%
Aug-03-26 07:30AM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Jul-30-26 07:43AM	Crescent Biopharma: Q2 Earnings Snapshot (Associated Press)
07:35AM	Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-23-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +7.58%
Jul-16-26 04:01PM	Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-14-26 09:45PM	Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Jun-26-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +9.24%
Jun-11-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
04:15PM	Loading…
Jun-02-26 04:15PM	Crescent Biopharma to Present at June Investor Conferences (GlobeNewswire) -13.77% +5.73%
May-29-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
May-21-26 05:30PM	Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (GlobeNewswire) +6.98%
May-12-26 04:30PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +6.23%
May-06-26 07:30AM	Crescent Biopharma to Present at May Investor Conferences (GlobeNewswire)
Apr-29-26 04:15PM	Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -12.60% +6.83%
Apr-24-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Mar-27-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +12.30% +9.63%
Mar-06-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +6.53%
Feb-26-26 08:05AM	Crescent Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-23-26 07:30AM	Crescent Biopharma to Present at March Investor Conferences (GlobeNewswire)
Feb-19-26 07:30AM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +20.78%
Feb-18-26 07:30AM	Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors (GlobeNewswire)
Feb-05-26 07:30AM	Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
04:05PM	Loading…
Jan-30-26 04:05PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) -5.47%
Jan-05-26 07:00AM	Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors (GlobeNewswire)
Dec-18-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.) -7.97%
Dec-05-25 09:36AM	Crescent and Kelun-Biotech swap cancer asset rights in double deal (Pharmaceutical Technology)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 06:35AM	Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors (GlobeNewswire)
06:30AM	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics (GlobeNewswire)
Nov-17-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Nov-06-25 07:40AM	Crescent Biopharma: Q3 Earnings Snapshot (Associated Press Finance) +5.39%
07:30AM	Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:30AM	Crescent Biopharma to Present at November Investor Conferences (GlobeNewswire)
Nov-04-25 09:05AM	Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Aug-28-25 07:30AM	Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire)
Jul-31-25 07:34AM	Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
07:32AM	Crescent Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-25 07:30AM	Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-05-25 04:01PM	GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals (Business Wire) -5.43%
May-14-25 07:02PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance) -5.50%
Apr-28-25 07:30AM	Crescent Biopharma Appoints David Lubner to Board of Directors (GlobeNewswire)
Apr-03-25 07:30AM	Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics (GlobeNewswire) -11.73%
Jan-14-25 09:34AM	GlycoMimetics and Crescent Biopharma Announce Merger Plans (TipRanks)
Nov-13-24 05:15PM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-12-24 08:00AM	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 (PR Newswire) -5.29%
Nov-06-24 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting (Business Wire)
Oct-30-24 08:31AM	GlycoMimetics Announces Merger with Crescent Biopharma (TipRanks) -6.84%
Oct-29-24 07:00AM	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma (Business Wire) +191.32%
06:30AM	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint (Business Wire)
Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynch Ryan	See Remarks	Sep 16 '26	Sale	17.90	240	4,296	13,631	Sep 18 04:03 PM
Pinkas Jan	Chief Scientific Officer	Sep 16 '26	Sale	17.90	658	11,778	21,581	Sep 18 04:03 PM
Im Ellie Eunkyung	Chief Medical Officer	Sep 16 '26	Sale	17.90	623	11,152	21,446	Sep 18 04:02 PM
Scalzo Richard William	Chief Financial Officer	Sep 16 '26	Sale	17.90	568	10,167	19,730	Sep 18 04:02 PM
Bispham Barbara Harlin	See Remarks	Sep 16 '26	Sale	17.90	620	11,098	18,710	Sep 18 04:02 PM
Brumm Joshua T	Chief Executive Officer	Sep 18 '26	Sale	16.71	7,837	130,956	271,765	Sep 18 04:02 PM
Brumm Joshua T	Chief Executive Officer	Sep 16 '26	Sale	17.90	1,610	28,819	279,602	Sep 18 04:02 PM
McNeill Jonathan	President and COO	Sep 18 '26	Sale	16.71	3,839	64,150	134,588	Sep 18 04:01 PM
McNeill Jonathan	President and COO	Sep 16 '26	Sale	17.90	731	13,085	138,427	Sep 18 04:01 PM
Joshua T Brumm	Officer	Sep 18 '26	Proposed Sale	17.18	9,013	154,843		Sep 17 04:33 PM
Jonathan McNeill	Officer	Sep 18 '26	Proposed Sale	17.18	4,415	75,850		Sep 17 04:32 PM
Jonathan McNeill	Officer	Sep 16 '26	Proposed Sale	18.80	804	15,115		Sep 16 03:09 PM
Joshua T Brumm	Officer	Sep 16 '26	Proposed Sale	18.80	1,771	33,295		Sep 16 03:09 PM
Fairmount Funds Management LLC	Director	Jul 16 '26	Buy	14.50	853,450	12,375,025	3,601,316	Jul 20 05:30 PM
Lynch Ryan	See Remarks	Jun 22 '26	Sale	17.99	465	8,365	13,871	Jun 23 04:04 PM
Pinkas Jan	Chief Scientific Officer	Jun 22 '26	Sale	17.99	1,288	23,171	22,239	Jun 23 04:04 PM
Scalzo Richard William	Chief Financial Officer	Jun 22 '26	Sale	17.99	1,112	20,005	20,298	Jun 23 04:03 PM
Bispham Barbara Harlin	See Remarks	Jun 22 '26	Sale	17.99	1,218	21,912	19,330	Jun 23 04:03 PM
Im Ellie Eunkyung	Chief Medical Officer	Jun 22 '26	Sale	17.99	1,219	21,930	22,069	Jun 23 04:02 PM
McNeill Jonathan	President and COO	Jun 22 '26	Sale	17.99	20,549	369,677	139,158	Jun 23 04:02 PM
Brumm Joshua T	Chief Executive Officer	Jun 22 '26	Sale	17.99	42,305	761,067	281,212	Jun 23 04:01 PM
Fairmount Funds Management LLC	Director	Dec 04 '25	Buy	13.41	1,360,000	18,237,600	2,747,866	Dec 08 04:30 PM

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

CEO & DirectorMr. Joshua T. Brumm

President & COODr. Jonathan McNeill M.D.

Chief Medical OfficerDr. Ellie Im M.D.

Chief Financial OfficerMr. Richard William Scalzo M.B.A.

Senior VP of FinanceMr. Ryan Lynch

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CBIO

Crescent Biopharma Inc

Upgrade your Finviz experience